Citation & Authors
Kidney Int Rep. 2026;11(3):103756.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
Preface
Most patients with type 2 diabetes and chronic kidney disease do not have albuminuria, but data on the potential benefits of SGLT2 inhibitors in this population are limited.
method
This population-based cohort study used Taiwan’s National Health Insurance Research Database from May 1, 2016, to December 31, 2021, to investigate associations between SGLT2 inhibitor use and outcomes in patients with type 2 diabetes and nonalbuminuric chronic kidney disease. Cox proportional hazards models compared the study and control groups.
result
Follow-up lasted 3 years. In the prematching intention-to-treat model, SGLT2 inhibitor use versus nonuse was associated with lower risks of dialysis (aHR 0.21; 95% CI 0.10–0.44; P<0.001), progression to macroalbuminuria (0.86; 0.79–0.94; P=0.001), major adverse cardiovascular events (0.85; 0.76–0.95; P=0.005), acute kidney injury (0.68; 0.56–0.82; P<0.001), and all-cause mortality (0.63; 0.52–0.76; P<0.001). Multivariable analyses after propensity score matching showed lower risks of progression to macroalbuminuria (0.84; 0.73–0.97; P=0.015) and all-cause mortality (0.40; 0.28–0.59; P<0.001) in users.
Conclusion
This nationwide cohort found that SGLT2 inhibitor use in patients with type 2 diabetes and nonalbuminuric chronic kidney disease was significantly associated with lower risks of progression to macroalbuminuria and all-cause mortality.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
